Skip to main content

Phase 3 Readout

ABBV: Phase 3 Topline: A Phase 3b/4 Randomized, Double-Blind, Double Dummy, Active Comparator-Controlled Study, Comparing t

July 15, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date
July 15, 2026
Company
AbbVie Inc. (ABBV)
BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout

Phase 3 Topline: A Phase 3b/4 Randomized, Double-Blind, Double Dummy, Active Comparator-Controlled Study, Comparing t

ABBV overview →
Indication
Rheumatoid Arthritis

Other upcoming events for ABBV

Phase 2 StartPhase 2 Start: A Phase 2, Open-Label, Master Protocol Study to Evaluate Safety and Efficacy of Treatment Combinatio
Phase 2 StartPhase 2 Start: A Phase 2 Open-Label Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotu
Phase 3 ReadoutPhase 3 Topline: Randomized, Double-blind, Placebo-Controlled, Multiple-Attack Study With an Open-Label Extension to
Phase 3 ReadoutPhase 3 Topline: A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy an